FDA shares new draft guidance for accelerated approval
The new FDA guidance outlines how surrogate or intermediate clinical endpoints can support accelerated approval.
The new FDA guidance outlines how surrogate or intermediate clinical endpoints can support accelerated approval.
What's Your Reaction?
